5 results
To assess the effect of SLT on the frequency of soft (stool of type 3, 4 or 5 on the Bristol Stool Form Scale (BSFS)) complete bowel movements (SCBMs) and SCBMs non-straining (NS) per week in subjects taking World Health Organisation (WHO) step II/…
The objective of the study is to assess the efficacy and safety of Alirocumab in patients with heterozygote familial hypercholesterolemia whose LDL-C level is higher than or equal to 160 mg/dL (4.14 mmol/L) on maximally tolerated statin therapy with…
Primary objective* To assess the long-term safety of alirocumab when added to currently available lipid-modifying drug therapy in patients with heterozygous familial hypercholesterolemia (heFH) who have completed one of the following studies:…
In the present study, we set out to evaluate arterial wall inflammation in patients at increased CV-risk with statin-associated muscle symptoms (SAMS), precluding effective statin therapy. Following twelve weeks of treatment with PCSK9-Ab, the…
To assess arterial wall inflammation, measured with 18F-FDG PET/CT scan, in patients with intermediate and severe FH phenotype, as well as the change in arterial wall inflammation following PCSK9 inhibition.